Spots Global Cancer Trial Database for Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL

Official Title: Safety and Efficacy of BT-007 CAR-T Cells in the Treatment of Patients With Relapsed/Refractory T Cell Lymphoblastic Lymphoma (R/R T-LBL)

Study ID: NCT05554575

Conditions

T Cell Lymphoblastic Lymphoma

Interventions

BT-007 CD7 CAR-T cells

Study Description

Brief Summary: This is a single center, single arm, open-lable phase I study to determine the safety and efficacy of T cells expressing CD7 chimeric antigen receptors (referred to as "BT-007 CAR-T cells") in patients with relapsed or refractory acute T cell lymphoblastic lymphoma (R/R T-LBL).

Detailed Description: Primary objective: To investigate the safety and efficacy of CD7 CAR-T cells in the treatment of patients with relapsed or refractory acute T cell lymphoblastic lymphoma (R/R T-LBL). Secondary objective: To assess the patient's quality of life after receiving the treatment.